Scotiabank initiated coverage on NewAmsterdam Pharma with a new price target
$NAMS
Biotechnology: Pharmaceutical Preparations
Health Care
Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00